{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease&page=10",
    "query": {
      "condition": "Parkinson Disease",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 1864,
    "total_pages": 187,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T12:57:25.926Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00465452",
      "title": "Impact of Switching to Continuous Release Dopamine Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Continuous Release Dopamine Agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Toledo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2007-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465452"
    },
    {
      "nct_id": "NCT02324426",
      "title": "CNS Uptake of Intranasal Glutathione",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Reduced Glutathione",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-12",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324426"
    },
    {
      "nct_id": "NCT00199368",
      "title": "An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Istradefylline ( KW-6002)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 1100,
      "start_date": "2004-10",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00199368"
    },
    {
      "nct_id": "NCT02803749",
      "title": "Buspirone in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Buspirone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-10",
      "completion_date": "2019-01-25",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02803749"
    },
    {
      "nct_id": "NCT00104585",
      "title": "Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 750,
      "start_date": "2004-07",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104585"
    },
    {
      "nct_id": "NCT02657655",
      "title": "Kinesia 360 Parkinson's Monitoring Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Kinesia 360",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Great Lakes NeuroTechnologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2016-01",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2018-02-19",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02657655"
    },
    {
      "nct_id": "NCT04476017",
      "title": "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "SAGE-718",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-07-31",
      "completion_date": "2022-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • Port Charlotte, Florida • West Palm Beach, Florida + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476017"
    },
    {
      "nct_id": "NCT04449484",
      "title": "Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "MEDI1341",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-08-04",
      "completion_date": "2022-01-05",
      "has_results": false,
      "last_update_posted_date": "2022-06-03",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04449484"
    },
    {
      "nct_id": "NCT00400634",
      "title": "Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])",
          "type": "DRUG"
        },
        {
          "name": "Sham Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-11",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00400634"
    },
    {
      "nct_id": "NCT06932809",
      "title": "Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tauopathies"
      ],
      "interventions": [
        {
          "name": "18F-JSS20-183A PET",
          "type": "DRUG"
        },
        {
          "name": "Brain MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Amyloid PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Neurological Assessments",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 90,
      "start_date": "2025-05-09",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-13T12:57:25.926Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06932809"
    }
  ]
}